ENHO and cardiovascular disorder: According to a study conducted in 2024 by Elfedawy et al, adropin can be associated with a biomarker for cardiovascular disease for patients that suffer from CRF.[24] The study indicated that adropin is an important factor of cardiovascular disease risk estimation in patients suffering from CRF as it also linked metabolic homeostasis and cardiovascular system.